Bivalirudin contraindications: Difference between revisions
Jump to navigation
Jump to search
No edit summary |
No edit summary |
||
| Line 5: | Line 5: | ||
==Title== | ==Title== | ||
Angiomax is contraindicated in patients with: | |||
Active major bleeding; | |||
<ref>{{Cite web | last = | first = | title = ANGIOMAX (BIVALIRUDIN) INJECTION, POWDER, LYOPHILIZED, FOR SOLUTION [THE MEDICINES COMPANY] | url = http://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=911cd48f-01ea-4dec-b30c-95e7e0ea9d2a | publisher = | date = | accessdate = 10 March 2014 }}</ref> | Hypersensitivity (e.g., anaphylaxis) to Angiomax or its components [see Adverse Reactions (6.3)].<ref>{{Cite web | last = | first = | title = ANGIOMAX (BIVALIRUDIN) INJECTION, POWDER, LYOPHILIZED, FOR SOLUTION [THE MEDICINES COMPANY] | url = http://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=911cd48f-01ea-4dec-b30c-95e7e0ea9d2a | publisher = | date = | accessdate = 10 March 2014 }}</ref> | ||
==References== | ==References== | ||
Revision as of 15:21, 10 March 2014
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1] Associate Editor(s)-in-Chief: Jesus Rosario Hernandez, M.D. [2]
Title
Angiomax is contraindicated in patients with:
Active major bleeding; Hypersensitivity (e.g., anaphylaxis) to Angiomax or its components [see Adverse Reactions (6.3)].[1]
References
- ↑ "ANGIOMAX (BIVALIRUDIN) INJECTION, POWDER, LYOPHILIZED, FOR SOLUTION [THE MEDICINES COMPANY]". Retrieved 10 March 2014.
Adapted from the FDA Package Insert.